This is a first-in-human (FIH), multicenter, open-label, phase I study of ABSK211 in participants with advanced solid tumors to evaluate safety, tolerability, PK and optimize the dosage.
Participants should understand, sign, and date the written informed consent form prior to screening.
Male or female age 18 years or older
Participants with histologically confirmed locally-advanced or metastatic solid tumors harboring KRAS alteration
ECOG performance status 0 or 1
Known allergy or hypersensitivity to any component of the investigational product
Participants who were previously treated with any inhibitors targeting specific KRAS alleles, pan-KRAS inhibitors, pan- or multi-RAS inhibitors, or any other treatments directly targeting RAS.
Has a known additional malignancy that is progressing or has required active treatment
Has swallowing dysfunction or malabsorption syndrome